Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
Johnson
K P
KP
Brooks
B R
BR
Cohen
J A
JA
Ford
C C
CC
Goldstein
J
J
Lisak
R P
RP
Myers
L W
LW
Panitch
H S
HS
Rose
J W
JW
Schiffer
R B
RB
Vollmer
T
T
Weiner
L P
LP
Wolinsky
J S
JS
D000276:Adjuvants, Immunologic / Q000266:history* / Q000627:therapeutic use; D004185:Disability Evaluation; D000068717:Glatiramer Acetate; D049673:History, 20th Century; D006801:Humans; D007279:Injections, Subcutaneous; D008134:Long-Term Care; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000266:history* / Q000628:therapy; D010455:Peptides / Q000266:history* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000266:history
D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate